{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T09:29:12Z","timestamp":1792229352253,"version":"4.4.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.beem.2015.09.004","type":"journal-article","created":{"date-parts":[[2015,10,15]],"date-time":"2015-10-15T00:15:12Z","timestamp":1444868112000},"page":"79-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Neuroendocrine tumours \u2013 Medical therapy: Biological"],"prefix":"10.1016","volume":"30","author":[{"given":"Anja","family":"Rinke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Krug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2015.09.004_bib1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.179.4068.77","article-title":"Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone","volume":"179","author":"Brazeau","year":"1973","journal-title":"Science"},{"key":"10.1016\/j.beem.2015.09.004_bib2","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2036.2009.04174.x","article-title":"Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours","volume":"31","author":"Modlin","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.beem.2015.09.004_bib3","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000335594","article-title":"ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms","volume":"95","author":"Caplin","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.beem.2015.09.004_bib4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/gut.50.1.52","article-title":"Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies","volume":"50","author":"Kulaksiz","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.beem.2015.09.004_bib5","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1210\/jc.2014-2699","article-title":"Somatostatin receptors in bronchopulmonary neuroendocrine neoplasms: new diagnostic, prognostic, and therapeutic markers","volume":"100","author":"Kaemmerer","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2015.09.004_bib6","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/0024-3205(82)90087-X","article-title":"SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action","volume":"31","author":"Bauer","year":"1982","journal-title":"Life Sci"},{"key":"10.1016\/j.beem.2015.09.004_bib7","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1365-2265.2005.02372.x","article-title":"Pharmacokinetic profile of lanreotide autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days","volume":"63","author":"Bronstein","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"Suppl. 1","key":"10.1016\/j.beem.2015.09.004_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000080741","article-title":"Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors","volume":"80","author":"Schmid","year":"2004","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.beem.2015.09.004_bib9","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/nrd1255","article-title":"Opportunities in somatostatin research: biological, chemical and therapeutic aspects","volume":"2","author":"Weckbecker","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.beem.2015.09.004_bib10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1073\/pnas.0136771100","article-title":"Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis","volume":"100","author":"Guillermet","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beem.2015.09.004_bib11","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/annonc\/mdl105","article-title":"Rationale for the use of somatostatin analogs as antitumor agents","volume":"17","author":"Susini","year":"2006","journal-title":"Ann Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.beem.2015.09.004_bib12","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1093\/annonc\/10.suppl_2.S31","article-title":"Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook","volume":"10","author":"Eriksson","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beem.2015.09.004_bib13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1210\/er.2000-0001","article-title":"The pathophysiological consequences of somatostatin receptor internalization and resistance","volume":"24","author":"Hofland","year":"2003","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2015.09.004_bib14","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM198609113151102","article-title":"Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue","volume":"315","author":"Kvols","year":"1986","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2015.09.004_bib15","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","article-title":"Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome","volume":"17","author":"Rubin","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beem.2015.09.004_bib16","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0","article-title":"Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance","volume":"88","author":"O'Toole","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.beem.2015.09.004_bib17","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/(SICI)1097-0142(19960115)77:2<402::AID-CNCR25>3.0.CO;2-4","article-title":"Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian trials in medical oncology group","volume":"77","author":"di Bartolomeo","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.beem.2015.09.004_bib18","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/00000421-200008000-00020","article-title":"Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors","volume":"23","author":"Ricci","year":"2000","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.beem.2015.09.004_bib19","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000082875","article-title":"Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide","volume":"80","author":"Ruszniewski","year":"2004","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.beem.2015.09.004_bib20","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2036.2009.04083.x","article-title":"Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR","volume":"30","author":"Toumpanakis","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.beem.2015.09.004_bib21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2011.04693.x","article-title":"Long-term results of treatment of malignant carcinoid syndrome with prolonged release lanreotide (Somatuline Autogel)","volume":"34","author":"Khan","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.beem.2015.09.004_bib22","first-page":"273","volume":"32","author":"Ruszniewski","year":"2014","journal-title":"ASCO Meet Abstr"},{"key":"10.1016\/j.beem.2015.09.004_bib23","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/ERC-11-0367","article-title":"Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study","volume":"19","author":"Kvols","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2015.09.004_bib24","series-title":"JCO","article-title":"A\u00a0multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors (NET) with disease-related symptoms inadequately controlled by somatostatin analogs","author":"Edward","year":"2013"},{"key":"10.1016\/j.beem.2015.09.004_bib25","doi-asserted-by":"crossref","first-page":"e73679","DOI":"10.1371\/journal.pone.0073679","article-title":"The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study","volume":"8","author":"Dobson","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.beem.2015.09.004_bib26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000111034","article-title":"Consensus guidelines for the management of patients with digestive neuroendocrine tumors\u2013well-differentiated jejunal-ileal tumor\/carcinoma","volume":"87","author":"Eriksson","year":"2008","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.beem.2015.09.004_bib27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2011-300831","article-title":"Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)","volume":"61","author":"Ramage","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.beem.2015.09.004_bib28","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00428-002-0609-x","article-title":"Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis","volume":"440","author":"Papotti","year":"2002","journal-title":"Virchows Arch"},{"key":"10.1016\/j.beem.2015.09.004_bib29","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1445-5994.2007.01371.x","article-title":"Severe hypoglycaemia after long-acting octreotide in a patient with an unrecognized malignant insulinoma","volume":"37","author":"Healy","year":"2007","journal-title":"Intern Med J"},{"key":"10.1016\/j.beem.2015.09.004_bib30","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00535-002-1170-8","article-title":"Octreotide in control of multiple liver metastases from gastrinoma","volume":"38","author":"Saijo","year":"2003","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.beem.2015.09.004_bib31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000098009","article-title":"Gastrinoma (duodenal and pancreatic)","volume":"84","author":"Jensen","year":"2006","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.beem.2015.09.004_bib32","doi-asserted-by":"crossref","first-page":"363","DOI":"10.7326\/0003-4819-103-3-363","article-title":"Pancreatic cholera syndrome: effect of a synthetic somatostatin analog on intestinal water and ion transport","volume":"103","author":"Santangelo","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beem.2015.09.004_bib33","first-page":"1259","article-title":"VIPomas: an update in diagnosis and management in a series of 11 patients","volume":"52","author":"Nikou","year":"2005","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.beem.2015.09.004_bib34","first-page":"989","article-title":"Use of a somatostatin analog (SMS 201-995) in the glucagonoma syndrome","volume":"100","author":"Altimari","year":"1986","journal-title":"Surgery"},{"key":"10.1016\/j.beem.2015.09.004_bib35","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000199835","article-title":"Octreotide (SMS 201-995) in the treatment of metastatic glucagonoma: report of one case and review of the literature","volume":"42","author":"Rosenbaum","year":"1989","journal-title":"Digestion"},{"key":"10.1016\/j.beem.2015.09.004_bib36","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000098011","article-title":"Rare functioning pancreatic endocrine tumors","volume":"84","author":"O'Toole","year":"2006","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.beem.2015.09.004_bib37","first-page":"92","article-title":"Cyclic ectopic cushing's syndrome and somatostatin analogue treatment","volume":"122","author":"Falhammar","year":"2009","journal-title":"N\u00a0Z Med J"},{"issue":"8","key":"10.1016\/j.beem.2015.09.004_bib38","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/annonc\/mdv041","article-title":"Pulmonary neuroendocrine (carcinoid) tumors: European neuroendocrine tumor society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids","volume":"26","author":"Caplin","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beem.2015.09.004_bib39","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beem.2015.09.004_bib40","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2015.09.004_bib41","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdh216","article-title":"Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system","volume":"15","author":"Oberg","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beem.2015.09.004_bib42","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1089\/jir.1987.7.429","article-title":"Virus interference. I. The interferon. By A. Isaacs and J. Lindenmann, 1957","volume":"7","author":"Isaacs","year":"1987","journal-title":"J\u00a0Interferon Res"},{"key":"10.1016\/j.beem.2015.09.004_bib43","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.0105-2896.2004.00204.x","article-title":"Interferons, interferon-like cytokines, and their receptors","volume":"202","author":"Pestka","year":"2004","journal-title":"Immunol Rev"},{"key":"10.1016\/j.beem.2015.09.004_bib44","doi-asserted-by":"crossref","first-page":"20059","DOI":"10.1074\/jbc.R700016200","article-title":"JAK-STAT signaling: from interferons to cytokines","volume":"282","author":"Schindler","year":"2007","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.beem.2015.09.004_bib45","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/10428199809068563","article-title":"The biology of interferon-alpha and the clinical significance of anti-interferon antibodies","volume":"29","author":"Hanley","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beem.2015.09.004_bib46","article-title":"The interferon receptors","volume":"24","author":"Pestka","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1016\/j.beem.2015.09.004_bib47","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000058529","article-title":"Interferon alpha induction of Stat1 and Stat2 and their prognostic significance in carcinoid tumors","volume":"60","author":"Zhou","year":"2001","journal-title":"Oncology"},{"key":"10.1016\/j.beem.2015.09.004_bib48","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/BF02303835","article-title":"Interferon-mediated activation of the STAT signaling pathway in a human carcinoid tumor","volume":"5","author":"Wang","year":"1998","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.beem.2015.09.004_bib49","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0016-5085(00)70143-0","article-title":"Molecular mechanism of interferon alfa-mediated growth inhibition in human neuroendocrine tumor cells","volume":"118","author":"Detjen","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.beem.2015.09.004_bib50","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1158\/0008-5472.CAN-06-2575","article-title":"SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells","volume":"67","author":"Zitzmann","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.beem.2015.09.004_bib51","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198307213090301","article-title":"Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome","volume":"309","author":"Oberg","year":"1983","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2015.09.004_bib52","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1200\/JCO.1989.7.7.865","article-title":"Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon","volume":"7","author":"Moertel","year":"1989","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beem.2015.09.004_bib53","first-page":"1297","article-title":"Treatment of malignant carcinoid tumors with human leukocyte interferon: long-term results","volume":"70","author":"Oberg","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.beem.2015.09.004_bib54","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/0277-5379(89)90107-7","article-title":"Treatment of malignant carcinoid tumors: a randomized controlled study of streptozocin plus 5-FU and human leukocyte interferon","volume":"25","author":"Oberg","year":"1989","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1016\/j.beem.2015.09.004_bib55","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3109\/02841869109092411","article-title":"The role of interferons in the management of carcinoid tumors","volume":"30","author":"Oberg","year":"1991","journal-title":"Acta Oncol"},{"key":"10.1016\/j.beem.2015.09.004_bib56","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/1097-0142(19900501)65:9<1883::AID-CNCR2820650902>3.0.CO;2-3","article-title":"Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors","volume":"65","author":"Eriksson","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.beem.2015.09.004_bib57","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/bjs.4149","article-title":"Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours","volume":"90","author":"K\u00f6lby","year":"2003","journal-title":"Br J Surg"},{"key":"10.1016\/j.beem.2015.09.004_bib58","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000335591","article-title":"ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes","volume":"95","author":"Jensen","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.beem.2015.09.004_bib59","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000335597","article-title":"ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary","volume":"95","author":"Pavel","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.beem.2015.09.004_bib60","first-page":"519","article-title":"Interferons in the management of neuroendocrine tumors and their possible mechanism of action","volume":"65","author":"Oberg","year":"1992","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.beem.2015.09.004_bib61","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.2007.13.6374","article-title":"Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b","volume":"26","author":"Yao","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beem.2015.09.004_bib62","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1677\/ERC-09-0104","article-title":"Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710","volume":"16","author":"Dahan","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2015.09.004_bib63","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1542-3565(05)00481-7","article-title":"Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial","volume":"3","author":"Arnold","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.beem.2015.09.004_bib64","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1200\/JCO.2003.12.142","volume":"21","author":"Faiss","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beem.2015.09.004_bib65","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S0140-6736(85)92235-4","article-title":"Regression of metastatic vipoma with somatostatin analogue SMS 201-995","volume":"1","author":"Clements","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2015.09.004_bib66","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1200\/JCO.1999.17.4.1111","article-title":"Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms","volume":"17","author":"Wymenga","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beem.2015.09.004_bib67","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/gut.38.3.430","article-title":"Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours","volume":"38","author":"Arnold","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.beem.2015.09.004_bib68","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/annonc\/mdj113","article-title":"Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma","volume":"17","author":"Panzuto","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beem.2015.09.004_bib69","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/1471-2407-13-427","article-title":"Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study","volume":"13","author":"Mart\u00edn-Richard","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.beem.2015.09.004_bib70","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beem.2015.09.004_bib71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/ERC-14-0360","article-title":"Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors","volume":"22","author":"Cives","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2015.09.004_bib72","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3109\/02841869309083913","article-title":"An update of the medical treatment of malignant endocrine pancreatic tumors","volume":"32","author":"Eriksson","year":"1993","journal-title":"Acta Oncol"},{"key":"10.1016\/j.beem.2015.09.004_bib73","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/0959-8049(92)90060-F","article-title":"Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours","volume":"28A","author":"Tiensuu Janson","year":"1992","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.beem.2015.09.004_bib74","first-page":"1381","article-title":"Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors","volume":"94","author":"Frank","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.beem.2015.09.004_bib75","first-page":"4463","article-title":"Treatment of metastatic neuroendocrine carcinomas based on WHO classification","volume":"25","author":"Artale","year":"2005","journal-title":"Anticancer Res"},{"key":"10.1016\/j.beem.2015.09.004_bib76","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1385\/MO:19:1:35","article-title":"Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs","volume":"19","author":"Fj\u00e4llskog","year":"2002","journal-title":"Med Oncol"},{"key":"10.1016\/j.beem.2015.09.004_bib77","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1089\/jir.2006.26.8","article-title":"Efficacy and tolerability of pegylated IFN-alpha in patients with neuroendocrine gastroenteropancreatic carcinomas","volume":"26","author":"Pavel","year":"2006","journal-title":"J\u00a0Interferon Cytokine Res"},{"key":"10.1016\/j.beem.2015.09.004_bib78","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3109\/02841869109092409","article-title":"Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide","volume":"30","author":"Oberg","year":"1991","journal-title":"Acta Oncol"},{"key":"10.1016\/j.beem.2015.09.004_bib79","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/1097-0142(19930701)72:1<244::AID-CNCR2820720143>3.0.CO;2-Q","article-title":"Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors","volume":"72","author":"Saltz","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.beem.2015.09.004_bib80","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1159\/000007693","article-title":"Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors","volume":"60","author":"Faiss","year":"1999","journal-title":"Digestion"},{"key":"10.1016\/j.beem.2015.09.004_bib81","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1111\/j.1572-0241.2000.03210.x","article-title":"The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors","volume":"95","author":"Ducreux","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.beem.2015.09.004_bib82","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/annonc\/mdi258","article-title":"Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment?","volume":"16","author":"Bajetta","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beem.2015.09.004_bib83","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.22272","article-title":"Lanreotide autogel every 6 weeks compared with lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a phase III study","volume":"107","author":"Bajetta","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.beem.2015.09.004_bib84","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1677\/erc.1.01200","article-title":"Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma","volume":"13","author":"Butturini","year":"2006","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2015.09.004_bib85","first-page":"692","article-title":"The treatment of neuroendocrine tumors with long-acting somatostatin analogs: a single center experience with lanreotide autogel","volume":"34","author":"Bianchi","year":"2011","journal-title":"J\u00a0Endocrinol Invest"}],"container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X15000937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X15000937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:50:10Z","timestamp":1761497410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X15000937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S1521690X15000937"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2015.09.004","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuroendocrine tumours \u2013 Medical therapy: Biological","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2015.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}